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Introduction: T cells and systemic lupus 
erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune 
disease that aﬄ   icts mainly women in the reproductive 
years. It is a multisystem disease aﬀ  ecting the joints, skin, 
kidneys and brain and is characterized by autoantibody 
production by dysregulated B cells, target organ 
inﬁ  ltration by inﬂ  ammatory T cells and aberrant immune 
cell activation due to abnormal antigen presenting cell 
(APC) function. While aberrant T cells provide help to 
auto  reactive B cells, they also inﬁ   ltrate target organs, 
caus  ing damage, and thus are key players in SLE disease 
patho  genesis. Understanding the underlying defects 
within T lymphocytes is of utmost importance not only 
for understanding disease pathophysiology, but also for 
identifying predictive biomarkers and better therapeutic 
targets. T lymphocytes from SLE patients are unique in 
that they resemble naïve or somewhat anergic T cells in 
certain ways, such as their reduced ability to produce 
cytokines like interferon-γ and IL2, but simultaneously 
bear characteristics reminiscent of activated/memory 
T cells, such as the overall increased tyrosine phosphory-
lation of signaling intermediates, accelerated calcium ﬂ  ux 
responses, altered expression of signaling subunits such 
as the T cell receptor (TCR) zeta and FcRγ, and 
expression of adhesion or costimulatory molecules such 
as CD44 and CD40L. Th   e following sections describe in 
detail these and other T cell signaling abnormalities that 
are responsible for their defective phenotype and func-
tion and may potentially contribute to disease pathogenesis.
Early signaling events
Lipid rafts
Lipid rafts are sphingolipid-cholesterol-GM1-rich micro-
domains bearing TCR-CD3 complexes and associated 
signaling molecules distributed on the T cell surface. In 
normal T cells, TCR stimulation leads to clustering of 
these rafts to aid formation of the immunological 
synapse, allowing for cognate interactions with corres-
ponding molecules on APCs. Freshly isolated SLE T cells, 
however, display pre-clustered lipid rafts, indicating that 
the T cells are ‘poised’ for activation. In addition, these 
lipid rafts contain an altered composition of residing 
molecules on their surface. Alterations include the 
increased expression of FcRγ, Syk, and phospholipase C 
(PLC)γ, with decreased expression of the lymphocyte 
kinase Lck. Th  e localization of tyrosine phosphatase 
CD45 within the lipid rafts and its association with and 
activation of Lck are abnormal, leading to the degradation 
and thus reduced expression of Lck [1-4]. Th  e  co  stimu-
latory molecule cytotoxic T lymphocyte associated 
antigen 4 (CTLA4), a signaling component of the lipid 
raft, is an important negative regulator of TCR activation. 
Expres  sion of CTLA4 is found to be increased in freshly 
isolated T cells from SLE patients [5]; paradoxically, how-
ever, it is unable to control the aberrant T cell activation. 
Blocking the CTLA4-B7 signaling pathway appears to 
impede disease progression in animal models of lupus, 
although timing of treatment is important, such that 
early treat  ment prevents or ameliorates disease [6,7]. 
Continuous exposure of T cells to autoantigen and/or 
circulating anti-CD3/TCR autoantibodies [8] may 
account for the observed aggregated lipid rafts on freshly 
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Th   e pre-aggregated lipid rafts contribute to the 
pathogenesis of SLE, as evidenced in the lupus-prone 
MRL/lpr mouse. In this mouse, the percentage of T cells 
with clustered lipid rafts increases with age and peaks 
before lupus pathology development. More importantly, 
acceleration of lipid raft aggregation leads to disease 
advancement, whereas disrup  tion of the aggregates 
delays pathology [9]. Ex vivo treatment of T lymphocytes 
from SLE patients with atorvastatin, an inhibitor of 
3-hyroxy-3-methylgluteryl CoA reductase that disrupts 
lipid rafts, showed reduced co-localization of CD45 and 
Lck, thus reducing the active form of Lck within the rafts. 
Furthermore, TCR activa  tion not only restored the ERK 
phosphorylation but also decreased their production of 
the cytokines IL6 and IL10, which are implicated in SLE 
pathogenesis. Th  ese results show that statins may have 
therapeutic value in restoring signaling defects in SLE T 
cells and potentially disease [10].
TCR-CD3 complex
Th   e TCR is the surface sensor for antigens presented to 
lymphocytes in the context of the MHC molecule by 
APCs. Th   e TCR α and β chains are closely coupled to the 
CD3 δ, ε, γ, and ζ chains to form the TCR-CD3 complex. 
Each subunit of the ζ chain bears three immunoreceptor 
tyrosine activation motifs (ITAMs); thus, the ζζ homo-
dimer bears a total of six ITAMs and is a critical signaling 
transducer of T cells. In naïve T cells, antigen recognition 
brings together the TCR, the co-receptor molecule (CD4 
or CD8) and the tyrosine phosphatase CD45 on the T cell 
surface within cholesterol-rich domains called lipid rafts. 
CD45 removes inhibitory phosphates from the Src family 
lymphocyte kinase (Lck), and the CD3ζ chain is phos-
phorylated at the six ITAMs by Lck. Th   e CD3ζ chain then 
recruits the zeta associated protein of 70 kDa (ZAP70) 
kinase, which is also phosphorylated by Lck. ZAP70 then 
phosphorylates the adaptor proteins Linker of activation 
in T cells (LAT) and SLP-76, thus transmitting the signal 
downstream into three distinct pathways. Th  e adaptor 
proteins bind and activate the enzyme PLCγ on one hand 
and activate the Ras-mitogen-activated protein kinase 
(MAPK) pathway through guanine nucleotide exchange 
factors on the other. PLCγ cleaves phosphatidylinositol 
bisphosphate into diacyl glycerol and inositol trisphos-
phate. Diacyl glycerol activates protein kinase C (PKC), 
which activates the transcription factor NF-κB. Inositol 
trisphosphate leads to opening of the calcium channels, 
increased intracellular calcium concentrations and acti-
va  tion of the phosphatase calcineurin, which dephos-
phorylates and activates the transcription factor Nuclear 
factor of activated T cells (NFAT). Finally, the Ras-MAPK 
cascade induces and activates fos protein, a component 
of the transcription factor Activated protein 1 (AP1). 
Activation of NF-κB, NFAT and AP1 leads to nuclear 
translocation of these factors and activation of target gene 
transcription, cell proliferation and diﬀ  erentiation [11].
Triggering of the TCR in SLE T cells leads to an 
abnormally accelerated and heightened tyrosine phos-
phory  lation of signaling intermediates, and increased 
calcium ﬂ   ux characterizing their hyper-responsive 
pheno  type [12]. Th  e stronger signaling is evidenced by 
the earlier and greater overall tyrosine phosphorylation 
of signaling intermediates. SLE T cells display a unique 
rewiring of the surface TCR-CD3 complex wherein 
expression of the CD3ζ chain is decreased in cells from a 
majority of patients [12] (Figure 1). Th   e lack of the CD3ζ 
chain in the TCR-CD3 complex is structurally and 
functionally replaced by the homologous Fc receptor 
gamma (FcRγ) chain [13]. FcRγ was initially identiﬁ  ed as 
the Fc portion of the IgE receptor in mast cells and has 
structural and functional similarity to the ζ chain, 
although the CD3ζ chain has three ITAMs whereas FcRγ 
has only one. Upon stimulation of SLE T cells, the FcRγ 
chain recruits the spleen tyrosine kinase (Syk) instead of 
the normally recruited ZAP70. Th   e FcRγ-Syk interaction 
is exponentially (>100-fold) stronger than that of the ζ 
chain-ZAP 70 combination, rendering a stronger down-
stream intracellular signal [14]. While this leads to abnor-
mally increased calcium inﬂ  ux, it does not translate into 
higher IL2-producing capacity of these cells. Rather, the 
SLE T cells are poor producers of IL2, rendering their 
somewhat ‘anergic’ phenotype. Interestingly, replenish-
ment of the CD3ζ chain in SLE T cells in vitro normalizes 
the intracellular calcium ﬂ   ux and more importantly 
restores IL2 production [15], thus suggesting a key role 
for the CD3ζ chain in the T cell defect. Th  us,  correction 
of a missing signaling molecule in SLE T cells may result 
in normalization of eﬀ  ector T cell function.
Th   e decreased expression of the CD3ζ chain in SLE T 
cells has been attributed to defects at multiple levels, 
including defective gene transcription [16], aberrant 
mRNA splicing [17], poor transcript stability of alter  na-
tive splice variants [18], and increased protein degrada-
tion by caspase-mediated [19], ubiquitin-proteasome-
mediated and lysosomal-mediated mechanisms [20]. Th  e 
transcriptional activity of the CD3ζ promoter is limited 
because of limited binding of the transcriptional 
enhancer E-74-like-factor (Elf)-1 and increased binding 
of the repressor c-AMP response element modulator 
(CREM)α [21], which is increased in SLE T cells. Th  e 
CD3ζ mRNA in SLE T cells is produced in many alter-
natively spliced forms lacking coding regions that may 
result in non-functional or unstable isoforms [17]. Th  e 
CD3ζ chain protein is degraded by ubiquitin-mediated 
proteolysis [22], lysosomal degradation [20] as well as by 
caspase 3, which is expressed at increased levels in SLE T 
cells [19]. Because replenishment of CD3ζ results in 
Moulton and Tsokos Arthritis Research & Therapy 2011, 13:207 
http://arthritis-research.com/content/13/2/207
Page 2 of 10increased production of IL2, understanding the molecu-
lar mechanisms that lead to its decreased production has 
allowed the proposition of interventions that are 
expected to lead to normalized T cell function. For 
example, inhibition of caspase 3 [19], blocking of mam-
malian target of rapamycin (mTOR) with rapamycin [23] 
and silencing of the transcriptional repressor CREMα 
[21] may be considered as therapeutic tools in SLE.
Kinases
Th  e restructuring of the SLE TCR is characterized by 
abnormally high expression of the Syk kinase. Normally, 
TCR stimulation leads to the recruitment of ZAP70 
kinase to the CD3ζ chain; in SLE T cells, however, the 
substituted FcRγ recruits Syk kinase. Th  e FcRγ-Syk 
interaction is signiﬁ  cantly stronger than that of the zeta-
ZAP 70 association, and contributes to the stronger 
down  stream signaling as evidenced by hyper-phos  phory-
lation of intermediate signaling molecules and increased 
calcium ﬂ  ux in SLE T cells. Th   e increased expression and 
activity of Syk in SLE T cells is evidenced by its increased 
expression in the lipid rafts and increased association 
with downstream molecules involved in actin polymeri-
zation and calcium signaling, namely Vav-1 and PLCγ1 
[24]. Accordingly, Syk inhibition with the pharmaco-
logical agent R406 led to retardation of actin polymeriza-
tion kinetics in SLE T cells. Inhibition of Syk using the 
R788 inhibitor not only suppresses the development of 
skin and kidney disease but also abolishes established 
disease in lupus-prone mice [25]. Th   erefore, Syk inhibi-
tion is under consideration for clinical trials in patients 
with SLE.
Phosphorylated PKB content is clearly increased in 
MRL-lpr CD4+ cells compared to control CD4+ cells and 
Figure 1. Schematic showing the T cell receptor signaling architecture in normal and systemic lupus erythematosus T cells. SLE, systemic 
lupus erythematosus; TCR, T cell receptor.
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inhibition of phosphoinositide 3-kinase (PI3K)γ by the 
compound AS605240 led to signiﬁ  cantly reduced severity 
of glomerulonephritis prolonged survival in lupus-prone 
MRL/lpr mice [26]. Should PI3Kγ levels be found to be 
increased in human SLE T cells, it should also be 
considered for therapeutic targeting.
Adhesion/co-stimulation
CD44, phosphorylated ezrin/radixin/moiesin
CD44 is a T cell surface adhesion molecule that recog-
nizes and binds to its ligand hyaluronic acid in tissues 
and thus enables T cells to migrate into peripheral 
tissues. Naïve T cells express low levels of CD44 whereas 
activated and memory T cells express high amounts of 
this membrane receptor. Th  e CD44 gene undergoes 
exten  sive alternative splicing of its variable exons, leading 
to the generation of numerous alternatively spliced iso-
forms. T cells from SLE patients express high amounts of 
certain CD44 isoforms (v3 and v6) and their expression 
correlates with a patient’s disease activity [27]. Renal 
biopsy of patients with lupus nephritis revealed T cells 
from kidneys to express CD44, and also showed phos-
phorylated ezrin/radixin/moiesin (pERM) proteins to be 
involved in the CD44 signaling cascade [28], suggesting 
that expression of these homing molecules may allow the 
T cells to migrate abnormally into the kidneys. pERM is 
responsible for the increased polarization, adhesion and 
migration of T cells in SLE patients, as evidenced by the 
presence of pERM+ T cells in kidney inﬁ  ltrates. In addi-
tion, CD44 requires pERM in order to acquire adhesive 
capacity. ERM is phosphorylated by the rho-associated 
protein kinase (ROCK) and its inhibition makes SLE 
T cells unable to adhere to hemagglutinin-coated mem-
branes [29]. Th  e ﬁ  nding of CD44+pERM+ cells in both 
peripheral blood and diseased kidneys of SLE patients 
suggests that T cells become activated and acquire patho-
genic potential while in the periphery and then migrate 
to target tissues and lead to pathology. More recently, 
ROCK was found necessary for the production of IL17, 
and treatment of lupus-prone mice with a ROCK inhibi-
tor led to improved disease [30]. Th  erefore, the ex vivo 
human studies and the preclinical data strongly urge the 
consideration of ROCK inhibitors in the treatment of 
SLE patients.
Signaling lymphocytic activation molecule family
Th  e signaling lymphocytic activation molecule (SLAM) 
family comprises nine transmembrane signaling proteins 
and is a subtype of the immunoglobulin superfamily. 
Th   ese proteins serve as co-stimulatory molecules on the 
surface of T cells and are involved in lineage commitment 
during hematopoiesis, T cell function as well as B cell 
activation and natural killer cell inhibition. Most have a 
unique tyrosine-based switch motif that has high aﬃ   nity 
for the SH2 domain-bearing molecules SLAM-associated 
protein (SAP) and EAT2. Genome-wide association 
studies in SLE patients’ families have shown the presence 
of a susceptibility locus on chromosome 1q23 that also 
includes the SLAM genes [31]. A recent study found 
defects within the SLAMF such that co-engagement of 
SLAMF3 or 6 with CD3 in human SLE T cells failed to 
restore IL2 production [32]. Further understanding of the 
role of the SLAM family molecules in human SLE will 
reveal their role in disease and potential use in therapy.
CD40 ligand/inducible T cell co-stimulator
Activated T cells express CD40 ligand (CD40L) and 
provide cognate help to CD40-expressing B cells via the 
CD40-CD40L interaction. SLE T cells not only show 
increased and prolonged expression of CD40L upon 
activation but also exhibit increased levels of baseline 
CD40L, which correlated with disease activity in some 
patients [33,34]. Reciprocally, hyperactive B cells can 
stimu  late T cells, which upregulate CD40L. Dysregulated 
T cells then provide help to autoreactive B cells, inducing 
the production of autoantibodies. Th   e increased expres-
sion of CD40 in the kidneys in SLE patients was shown to 
correlate with the presence of CD40L-expressing peri-
pheral blood mononuclear cells. Preliminary clinical 
trials using two diﬀ  erent anti-CD40L antibodies, although 
showing promising results [35], led to severe unforeseen 
adverse eﬀ  ects [36]. Despite interesting preclinical data 
on the therapeutic potential of the disruption of the 
CD40-CD40L interaction, clinical eﬀ  orts so far have not 
met the predictions.
Another co-stimulatory molecule - inducible T cell co-
stimulator (ICOS) - is required for controlling the local 
inﬂ  ammatory eﬀ  ector functions of T cells inﬁ  ltrating the 
kidneys in MRL/lpr lupus-prone mice [37]. ICOS is also 
needed for IL21 secretion by extrafollicular helper T cells 
as well as plasma cell diﬀ  erentiation and IgG production 
in chronic autoimmunity evidenced in the lupus-prone 
mice lacking ICOS [38]. Th  ese studies suggest the 
potential importance of ICOS blockade as a therapeutic 
measure for autoimmune disease.
Intermediate signaling events
MAPK signaling pathway
Abnormalities in the MAPK signaling pathway have been 
reported in SLE T cells and include an impaired extra-
cellular signal-regulated kinase (ERK) signaling cascade. 
Th   e ERK signaling is diminished in SLE T cells [39]. Ras 
activation is shown to be abnormal in SLE patients [39], 
and altered Ras guanyl nucleotide releasing protein 1 
(RasGRP1) and PKCδ activation are linked to this defect 
[40,41]. Defective PKCδ activation leads to abnormal ERK 
pathway signaling, resulting in DNA hypomethy lation, 
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[42]. Decreased phosphorylation of PKCδ, ERK, MEK 
and Raf aﬀ   ects DNA methylation of target genes by 
leading to decreased expression of the DNA methyl 
transferase (DNMT). Accordingly, T cells from SLE 
patients have reduced levels of the enzyme DNMT1. 
While the exact link between the defective MAPK signal-
ing and autoimmunity is incompletely understood, two 
important consequences are the eﬀ  ect on DNA methy-
lation and the eﬀ  ect on reduced c-fos expression, which 
is a component of the AP1 transcription factor.
mTOR
Production of reactive oxygen intermediates and ATP 
synthesis are critical determinants of T cell activation, 
proliferation, cytokine production and cell death. 
Reactive oxygen intermediate and ATP generation are 
tightly regulated by the mitochondrial transmembrane 
potential. Persistent mitochondrial hyperpolarization, 
increased reactive oxygen intermediate production and 
ATP depletion in SLE T cells are responsible for their 
increased spontaneous and decreased activation-induced 
apoptosis. mTOR, a serine threonine kinase member of 
the PI3K-related kinase family, is a sensor of the mito-
chondrial transmembrane potential and is increased in 
SLE T cells [20]. Furthermore, nitric oxide-induced 
mTOR activation leads to lysosomal degradation of the 
CD3ζ chain through a HRES/Rab4-dependent pathway. 
HRES/Rab4 is a small GTPase that regulates endocytic 
recycling of surface receptors by the early endosomes 
[20]. mTOR inhibition in patients with SLE resulted in 
clinical improvement [23], and therefore a proper trial is 
warranted.
Gene transcription
CD3ζ/FcRγ transcription
Elf-1 is a member of the Ets family of transcription 
factors and is shown to bind and activate transcription of 
the  CD3ζ gene. Examination of ELF-1 in SLE patients 
showed two subsets of patients - one that expressed 
reduced amounts of the 98-kDa DNA binding form of 
the ELF-1 protein and another that showed reduced 
binding capacity to the CD3ζ promoter [16]. In addition, 
protein phosphatase (PP)2A dephosphorylates Elf-1 at 
Th  r231, resulting in limited expression and binding 
activity of the 98-kDa form. Th   us, the lack of a functional 
Elf-1 accounts for the reduced CD3ζ transcription in SLE 
T cells. Normal T cells when stimulated generate 
eﬀ   ectors that downregulate CD3ζ and concomitantly 
upregulate FcRγ in the TCR complex, thus functionally 
replacing the CD3ζ chain [43]. In SLE T cells, recon-
stitution of the CD3ζ chain reciprocally leads to down-
regulation of the FcRγ and restoration of calcium ﬂ  ux 
and IL2 production [15]. Interestingly, Elf-1 was also 
shown to bind GGAA elements in the FcRγ promoter 
and suppress FcRγ expression [44], indicating that Elf-1 
may act as a molecular switch in the reciprocal regulation 
of CD3ζ and FcRγ in SLE T cells. Th   e reduced expression 
of Elf-1 in SLE T cells may partly explain the increased 
expression of FcRγ concomitant with the reduced 
expression of CD3ζ.
IL2 transcription
TCR triggering induces intracellular signaling cascades, 
ultimately leading to gene transcription. In addition to 
the aberrations in signaling within SLE T cells a number 
of defects in the expression and/or function of trans-
cription factors are observed in SLE T cells. SLE T cells 
are poor producers of the vital growth and proliferation-
inducing cytokine IL2. Defective transcription is an 
important factor of this deﬁ  ciency. NF-κB, NFAT, AP1, 
CREB (cAMP response element-binding) and CREM are 
transcription factors involved in IL2 transcription (Figure 2). 
NF-κB is a heterodimer of the p65/p50 subunits and the 
expression of the p65 subunit is decreased in SLE T cells 
[45].
Th  e AP1 family of transcription factors is formed by 
heterodimers and homodimers of fos (v-fos, c-fos, fosB, 
fra1, and fra2) and jun (v-jun, c-jun, jun-b, jun-d) 
proteins [46]. Upon antigenic stimulation, the jun and fos 
proteins are expressed, and AP1 (especially the c-fos/c-
jun heterodimers) binds to the IL2 promoter. Decreased 
c-fos expression is responsible for reduced AP1 binding 
activity to the IL2 promoter in SLE T cells [47].
An imbalance between the transcription factors CREB 
and CREMα plays an important role in the regulation of 
IL2 production in SLE T cells. Th   e CREM gene undergoes 
alternative splicing to produce many isoforms, some of 
which are transcriptional activators, and others repres-
sors such as CREMα. Both activated CREB and CREMα 
reciprocally bind to a CRE site at position -180 on the IL2 
promoter. Active (phosphorylated) CREB is a transcrip-
tional activator of IL2 while phosphorylated CREMα is a 
transcriptional repressor of the IL2 gene. Reduced 
production of IL2 by SLE T cells is regulated in part by 
the increased expression and activity of CREMα. 
Decreased protein kinase A activity leads to reduced 
phosphorylation of CREB [48], thus reducing the availa-
bility of phosphorylated CREB for binding the IL2 
promoter. Additionally, abnormally increased expression 
of the PP2A enzyme, which dephosphorylates CREB, 
leads to reduced availability of phosphorylated CREB for 
binding to the IL2 promoter [49]. CREMα is phos  phory-
lated by a number of kinases, including the calcium/
calmodulin-dependent kinase IV (CAMKIV). Increased 
expression of CAMKIV is observed in the nucleus of SLE 
T cells. Treatment of normal T cells with SLE serum, 
which presumably leads to triggering of the TCR by 
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activation and nuclear translocation of CAMKIV and 
increased complex formation at the -180 site of the IL2 
promoter [8]. CAMKIV is increased also in T cells from 
the MRL/lpr lupus-prone mouse. Administration of a 
CAMKIV inhibitor to these mice was able to prevent and 
even correct disease pathology [50].
NFAT binds to promoters of the genes encoding IL2 
and CD40L and activates their transcription [51], and 
NFAT expression is abnormally high in SLE T cells. 
While this accounts for increased expression of CD40L, 
it does not promote increased IL2 production. Th  e 
reason for this discrepancy is that while NFAT can alone 
bind to and activate the CD40L promoter, binding to the 
IL2 promoter requires AP1 binding to adjacent sites. 
Defective AP1 activity thus hampers the NFAT action on 
IL2 transcription. In resting T cells, NFAT is phos-
phorylated and inactive in the cytoplasm. Upon T cell 
stimulation, dephosphorylation by the calcium res  ponsive 
calcineurin phosphatase, NFAT translocates into the 
nucleus and activates gene transcription. In SLE T cells, 
the increased calcium ﬂ   ux with resultant in  creased 
calcineurin expression leads to increased dephos-
phorylation of NFAT and thus increased availa  bility 
inside the nucleus and aberrant target gene expression.
IL17 transcription
IL17 has recently emerged as a key inﬂ  ammatory cyto-
kine, playing a central role in the pathogenesis of several 
autoimmune diseases, including SLE [52]. Serum IL17 
levels are increased in patients with SLE [53] and the 
frequency of IL17-producing T cells is increased in 
peripheral blood of patients with SLE [54]. An expanded 
population of CD3+CD4-CD8- double negative T cells 
was shown to produce increased amounts of IL17 in SLE 
patients. Furthermore, T cell inﬁ  ltrates in the kidneys 
were composed of double negative and IL17-producing 
T cells in patients with lupus nephritis [54]. Diﬀ  eren  tiation 
Figure 2. Schematic showing transcription factors involved in IL2 production in T cells. AP1, activated protein 1; CAMKIV, calcium/calmodulin-
dependent kinase IV; CREB, cAMP response element-binding; CREM, cAMP response element modulator; MAPK, mitogen-activated protein kinase; 
NFAT, nuclear factor of activated T cells; PKC, protein kinase C; PP, protein phosphatase.
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the presence of the inﬂ  ammatory cytokines IL6, IL23, 
IL21 and transforming growth factor-β, although human 
memory T cells are capable of producing IL17 with only 
CD3 CD28 priming [55,56]. IL23 is required to drive this 
diﬀ  erentiation, while IL21 sustains and is required for 
maintenance of IL17 production. IL6, IL21 and IL23 all 
activate STAT3, which can bind and activate the IL17 and 
IL21 genes directly [57]. Th  e expression and activity of 
STAT3 is increased in SLE T cells and is responsible in 
part for the enhanced chemokine-mediated migration of 
these cells [58]. Th  e  IL17 gene transcription is regulated 
by the retinoid related orphan receptor RORγt and RORα 
transcription factors. RORγt is expressed exclusively in 
Th  17 cells and is necessary for IL17 production [59]. 
Aside from the pro-inﬂ  ammatory  eﬀ  ects  mediated 
directly by IL17, it can also contribute to pathogenesis 
through its eﬀ  ect on other cell types. High levels of anti-
dsDNA IgG and IL6 were produced by peripheral blood 
mononuclear cells from patients with lupus nephritis 
when cultured with IL17 [60], suggesting its role in B cell 
activation. Genetic disruption of the IL23 receptor in the 
lupus prone B6.lpr mouse results in reduc  tion of the 
numbers of double negative cells, reduced IL17 
production, and improved renal pathology. Similarly, 
blockade of IL23 with an anti-IL23 antibody improved 
disease manifestations [61]; therefore, disrup  tion of the 
path from IL23 to IL17 may be of clinical value.
Alternative splicing in systemic lupus 
erythematosus
T cells from patients with SLE display abnormal alter-
native splicing of a number of genes involved in diverse 
functions, such as signaling, homing and transcription 
regulation. Examples include the signaling molecule 
CD3ζ, adhesion molecule CD44 and the transcription 
factor CREM. Polymorphisms and mutations in the CD3ζ 
gene within the 5’ UTR, the coding region as well as the 
3’ UTR have been reported. Notably, a 3’ UTR splice 
variant with reduced mRNA stability is expressed in 
increased amounts in SLE T cells (Figure 3) [18], likely 
due to the reduced expression of the serine arginine 
splicing factor ASF/SF2, which has been shown to repress 
the generation of this unstable isoform [62]. Th  e  CREM 
gene undergoes splicing to produce distinct isoforms 
with opposing roles in transcription regulation - some 
being transcriptional activators, such as CREMtau2α, 
while others repress transcription, such as CREMα and 
inducible cAMP early repressor ICER. Increased expres-
sion and activity of CREMα contributes to the defective 
IL2 transcription in SLE T cells [63]. Alternative splicing 
of CD44 leading to the expression of CD44v3 and 
CD44v6 in SLE T cells was discussed above. Under-
standing the regulation of alternative splicing of these 
molecules in SLE T cells may lead to identiﬁ  cation of 
potential therapeutic targets.
Epigenetics
DNA methylation leads to chromatin inactivation and 
suppression of gene expression whereas hypomethylation 
of DNA regulatory elements activates gene expression. 
Hypo  methylation is a characteristic of several genes 
involved in SLE T cell pathophysiology and contributes 
to the overexpression of genes responsible in lupus patho-
genesis and disease development [64]. Typical examples 
of genes that are involved in the pathogenesis of SLE and 
have been found hypomethylated include CD11a, per-
forin, CD70 and CD40L [42]. Hypomethylation of the 
PP2A promoter is a contributing factor responsible for 
the overexpression of this enzyme in SLE T cells [65]. 
Expression and activity of the DNMT enzyme, respon-
sible for DNA methylation, were reduced in T cells from 
Figure 3. Schematic showing the CD3ζ gene. Genomic DNA with eight exons (top), the mRNA with a full-length 906-bp 3’ UTR (WT; middle) and 
the 344-bp alternatively spliced (AS) 3’ UTR variant (bottom). SLE T cells express increased amounts of the unstable AS splice variant relative to the 
stable WT isoform.
I II III IV V VI VII VIII CD3 zeta 
Genomic DNA
WT CD3ζ ζ Normal
(Stable)
AS CD3ζ Lupus 
(Unstable)
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Recent evidence shows the role of the growth arrest and 
DNA damage-induced (GADD) 45alpha gene in promot-
ing lupus-like autoimmunity by inducing gene hypo-
methylation in CD4+ T cells from SLE patients [67].
Conclusion
While there is a wide range of anomalies within SLE 
T  cells, certain common themes emerge and provide 
clues to central molecular mechanisms linking these 
various defects. Th  ese include chronic activation, epi-
genetic mechanisms, such as defective DNA methylation, 
and aberrant gene regulation, such as defective alter-
native splicing. Several defects observed in the SLE TCR 
signaling pathway are suggestive of an activation state 
and may be due to activation by APC and/or auto-
antibodies. For example, activation induces changes in 
the expression of Lck, CD3ζ, FcRγ, ZAP70, and Syk, 
phosphorylation of intermediates, and calcium ﬂ  uxing, 
many of which are also observed in SLE T cells. However, 
SLE T cells concurrently exhibit unique features that do 
not occur in normal activated T cells. For example, while 
the activation of normal T cells induces downregulation 
of the ζ chain, there is no downregulation of the mRNA - 
this is not observed in SLE T cells wherein the trans-
cription of the ζ chain is defective due to speciﬁ  c aber-
rations, such as reduced activity of the trans  criptional 
enhancer Elf-1 and others as explained in the sections 
above. Aberrant DNA methylation aﬀ  ects a number of 
genes in SLE patients, such as those encoding CD40L, 
CD70, CD11a, and PP2A. Aberrant alternative splicing of 
many genes (CD3ζ,  CD44,  CREM) is observed in SLE 
T  cells and may reﬂ   ect a global deregulation of this 
process, which may be of genetic origin or may reﬂ  ect 
defects in the cellular microenvironment.
In summary, T cells from SLE patients have several 
biochemical abnormalities endowing them with a hyper-
excitable phenotype but a defective gene transcription 
program. Th  ese result in a peculiar cell type with 
properties of activated/eﬀ  ector cells on the one hand but 
a somewhat anergic state on the other. Many molecules 
involved in the development of this phenotype have been 
identiﬁ   ed and should eventually lead to better under-
standing and management of this complex disease. SLE is 
a heterogeneous disease, and it is likely that several 
molecular defects result in the same/similar clinical out-
comes. It would be interesting and important to identify 
links between these signaling defects and clinical proﬁ  les 
of SLE patients. Simultaneous study of all abnormally 
expressed genes may provide additional insights into the 
identiﬁ  cation of subgroups among patients with SLE who 
share common biochemical aberrations. Identiﬁ  cation of 
such groups of patients may lead to the suggestion of 
speciﬁ  c treatment(s) able to correct deﬁ  ned abnor  malities. 
Our laboratory has initiated such an approach [68] and 
preliminary data along these lines are promising.
Th  e elucidation of aberrant signaling and gene trans-
cription in T cells from SLE patients is important, as this 
will lead to the identiﬁ  cation of novel drug targets, gene 
therapeutic measures, and, importantly, disease-predicting 
biomarkers. In this review, we have discussed the signaling 
and gene transcription aberrations in T lympho  cytes, and 
pointed out targets that can be exploited therapeutically. 
We have paid attention to abnormalities ﬁ  rst detected in 
human SLE T cells and then validated in lupus-prone 
mice using drug inhibitors or genetic manipulations. Syk, 
ROCK and CAMKIV inhibition as discussed herein 
deserve proper clinical consideration. In addition, inhibi-
tion of the IL23-IL17 axis deserves consideration for 
clinical trials using either anti-IL17 or IL23 antibodies or 
a decoy IL23 receptor. While B cell depletion has 
beneﬁ  ted a number of SLE patients, a clinical trial on 
B cell depletion therapy has yielded negative results and 
some biologics such as anti-Blys therapy have had mild 
eﬀ  ects.  Th  is should direct our attention also to the 
development of therapeutic targets that correct T cell 
function. A subset of patients may respond well to B-cell-
directed therapy, whereas another subset to T-cell-
modifying approaches. Th   e extremely complex nature of 
the disease, with heterogeneity not only at the clinical 
level but also at the molecular level, suggests the need for 
a case-by-case treatment modality rather than a blanket 
approach.
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